Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 6:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 132 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ketoconazole Clear all
Completed Phase 1 Interventional Results available

Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

NCT01324310
View directory record Official record
Conditions
Hematologic Malignancy, Malignant Lymphoma
Interventions
Romidepsin, Ketoconazole
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Sarasota, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

Ketoconazole and Dexamethasone in Prostate Cancer

NCT01036594
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ketoconazole, Hydrocortisone, Dexamethasone
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 16, 2026, 6:56 PM EDT
Terminated Phase 2Phase 3 Interventional

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

NCT00675714
View directory record Official record
Conditions
Burns
Interventions
Stable Isotope Infusion Study, Collection of blood and tissues, Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI, Humatrope, Ketoconazole, Oxandrolone, Propranolol, Oxandrolone and propranolol combined, Humatrope and propranolol combined, Placebo, Exercise--Hospital supervised intensive exercise program, Home exercise program
Procedure · Drug · Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 80 Years
Enrollment
1,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.

NCT06305637
View directory record Official record
Conditions
Tinea Versicolor
Interventions
Ketoconazole Shampoo, 2%, Ketoconazole Shampoo, 2% (Reference Standard), Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Not applicable Interventional

A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems

NCT00002304
View directory record Official record
Conditions
Candidiasis, Esophageal, HIV Infections
Interventions
Ketoconazole, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
41
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer

NCT00014352
View directory record Official record
Conditions
Prostate Cancer, Thromboembolism
Interventions
docetaxel, doxorubicin hydrochloride, estramustine phosphate sodium, ketoconazole, warfarin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 16, 2026, 6:56 PM EDT
Active, not recruiting Phase 2 Interventional Results available

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

NCT00859781
View directory record Official record
Conditions
Prostate Cancer
Interventions
177Lu-J591, Ketoconazole, Hydrocortisone, 111In-J591
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00460031
View directory record Official record
Conditions
Prostate Cancer
Interventions
ketoconazole, lenalidomide, therapeutic hydrocortisone
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
6
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult Volunteers

NCT01476800
View directory record Official record
Conditions
Healthy Subjects, Pharmacokinetics of YM178
Interventions
YM178 OCAS, Ketoconazole
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
19 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers

NCT01591850
View directory record Official record
Conditions
Healthy Volunteer
Interventions
RO5093151, atazanavir, ketoconazole, rifampicin, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Merritt Island, Florida
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction

NCT02256865
View directory record Official record
Conditions
Insulin Resistance
Interventions
Ketoconazole, Hydrocortisone, Testosterone, Placebo for ketoconazole, Placebo for hydrocortisone, Placebo for testosterone
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
22 Years to 45 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2023
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 16, 2026, 6:56 PM EDT
Completed No phase listed Observational

Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy

NCT00002924
View directory record Official record
Conditions
Prostate Cancer
Interventions
mutation analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Male only
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
49
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 16, 2026, 6:56 PM EDT
Terminated Phase 2 Interventional Results available

Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer

NCT02494713
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, Doxorubicin, Ketoconazole, Docetaxel, Estramustine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet

NCT01240226
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0941, ketoconazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Ketoconazole on the Pharmacokinetics of Refametinib

NCT01925638
View directory record Official record
Conditions
Drug Interactions
Interventions
BAY86-9766, Ketoconazole
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Early Phase 1 Interventional

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash

NCT03471364
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Ketoconazole, Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
6
States / cities
Danville, Illinois • Urbana, Illinois • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 3 Interventional Results available

Open-label Treatment in Cushing's Syndrome

NCT03621280
View directory record Official record
Conditions
Cushing Syndrome, Cushing Disease
Interventions
Levoketoconazole
Drug
Lead sponsor
Cortendo AB
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Fort Lauderdale, Florida • Atlanta, Georgia • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 16, 2026, 6:56 PM EDT
Terminated Phase 2 Interventional

A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer

NCT00006371
View directory record Official record
Conditions
Prostate Cancer
Interventions
aminoglutethimide, ketoconazole, therapeutic hydrocortisone
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults

NCT00460707
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Casopitant 150 mg, Ketoconazole, Casopitant 150 mg matching placebo, Casopitant 50 mg, Casopitant 50 mg matching placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
3
States / cities
Overland Park, Kansas • Buffalo, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy Subjects

NCT01363778
View directory record Official record
Conditions
Healthy
Interventions
tivozanib
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream

NCT01836198
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2409021, Gemfibrozil, Ketoconazole, Clarithromycin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer

NCT00298155
View directory record Official record
Conditions
Cancer, Prostate Neoplasms
Interventions
goserelin with dutasteride, goserelin with bicalutamide and dutasteride, goserelin with bicalutamide and dutasteride and ketoconazole
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer

NCT00673127
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ketoconazole, Hydrocortisone and Dutasteride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
6
States / cities
Baltimore, Maryland • Boston, Massachusetts • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Two Types of Treatment in Restoring Muscle After Hip or Knee Surgery

NCT00393848
View directory record Official record
Conditions
Hip Fracture, Osteoarthritis, Femur Head Necrosis
Interventions
Essential amino acid supplement, Ketoconazole, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
30 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 16, 2026, 6:56 PM EDT